Nösslinger Hannes, Mair Ewald, Oostingh Gertie J, Ahlgrimm-Siess Verena, Ringauf Anna, Lang Roland
Department of Nutrition and Dietetics, Hospital of Merano (SABES-ASDAA), Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, 39012 Merano-Meran, Italy.
Registered pediatrician (SABES-ASDAA), 39031 Brunico-Bruneck, Italy.
Diagnostics (Basel). 2024 May 8;14(10):976. doi: 10.3390/diagnostics14100976.
ImmunoCAP ISAC E112i (ISAC) and Allergy Explorer 2 (ALEX) detect specific immunoglobulin E (IgE) reactivity. Both multiplex assays contain molecular allergens and ALEX additionally includes allergen extracts and inhibitors that block the binding of IgE to cross-reacting carbohydrate determinants (CCDs). This study aimed to compare the performance of ISAC and ALEX by determining the IgE reactivity against allergen extracts and/or allergen components and by using qualitative, semiquantitative, and quantitative analyses of all comparable allergen components in sera from 216 participants recruited in South Tyrol/Italy. For extract sensitization in ALEX, the analysis revealed negative corresponding allergen components in 18.4% and at least one positive corresponding allergen component in 81.6% of all cases. For ISAC, the corresponding results were 23.5% and 76.5% of cases, respectively. The ALEX CCD inhibitor eliminated CCD-positive signals detected by ISAC in 88.5% of cases. Based on sensitization values of 0.3-14.9 ISU or kU/L, there was good agreement between ALEX and ISAC, although ALEX showed higher values than ISAC. The addition of allergen-extract tests in ALEX resulted in the detection of more sensitizations than with corresponding allergen components alone. In the range of <15 ISU or kU/L, ALEX may be more effective in detecting sensitizations.
免疫捕获ISAC E112i（ISAC）和过敏探索者2（ALEX）可检测特异性免疫球蛋白E（IgE）反应性。这两种多重检测均包含分子变应原，且ALEX还额外包含变应原提取物和可阻断IgE与交叉反应性碳水化合物决定簇（CCD）结合的抑制剂。本研究旨在通过测定针对变应原提取物和/或变应原成分的IgE反应性，并对从意大利南蒂罗尔招募的216名参与者血清中所有可比较的变应原成分进行定性、半定量和定量分析，来比较ISAC和ALEX的性能。对于ALEX中的提取物致敏情况，分析显示在所有病例中，18.4%的病例对应的变应原成分呈阴性，81.6%的病例至少有一个对应的变应原成分呈阳性。对于ISAC，相应结果分别为23.5%和76.5%的病例。ALEX的CCD抑制剂在88.5%的病例中消除了ISAC检测到的CCD阳性信号。基于0.3 - 14.9 ISU或kU/L的致敏值，ALEX和ISAC之间具有良好的一致性，尽管ALEX显示的值高于ISAC。在ALEX中增加变应原提取物检测比仅使用相应的变应原成分能检测到更多的致敏情况。在<15 ISU或kU/L的范围内，ALEX在检测致敏方面可能更有效。
